HR-4132-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Diana Harshbarger (R-TN)
What it does
This bill would let drug manufacturers provide FDA-required prescribing information electronically instead of as printed paper inserts, as long as prescribers and pharmacists can still request paper copies at no extra cost. It would require HHS to issue implementing regulations within 1 year and hold a public workshop within 2 years on optimizing the format of this information.
Who benefits
Drug manufacturers, who would save printing and distribution costs; pharmacies and healthcare systems that adopt electronic records, which could get faster access to updated safety information; environmental interests, due to reduced paper waste; and prescribers who prefer digital lookup tools.
Who is hurt
Prescribers and dispensers without reliable internet or electronic health record access, particularly in some rural or under-resourced clinics, who may face friction requesting paper copies; patients indirectly if information access is delayed during technical outages; and print/distribution businesses that currently supply paper labeling services.
Supporters argue
Supporters argue that prescribing information is frequently updated with new safety data, and electronic distribution allows prescribers to access the most current version instantly rather than relying on potentially outdated paper inserts. They contend this modernizes a decades-old requirement, reduces manufacturer costs and paper waste, while the bill's opt-in paper request provision protects those who still need physical copies.
Opponents argue
Opponents argue that not all prescribers and dispensers, especially in smaller or rural practices, have seamless access to reliable internet or electronic systems, which could create delays or gaps in accessing critical safety information during the transition. They contend that shifting the default to electronic-only communication places the burden on healthcare providers to actively request paper copies, which may not always be practical in time-sensitive clinical situations.
Constitutional context
Congress is regulating the labeling and distribution requirements for drugs moving in interstate commerce under the Commerce Clause (Art. I, §8, cl. 3), an area of well-established federal authority reflected in the existing Federal Food, Drug, and Cosmetic Act framework. There is no clear novel constitutional question raised by this bill.
Checks and balances
Congress amends the underlying statute directly and delegates specific implementing rulemaking to HHS/FDA with a defined deadline, and courts would review any resulting regulations under ordinary administrative law standards, including post-Loper Bright independent judicial interpretation of the statute.
Historical precedent
FDA has previously permitted electronic-only prescribing information for certain products through prior rulemaking (e.g., the 2014 rule allowing electronic distribution for prescribing information to prescribers), though this bill would codify and expand that approach in statute.